Program
Oxymetazoline
Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.
Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 60 open or running | phase 3since Mar 21, 2014 | Apr 13, 2012 | none ahead |
| RDD Pharma | 20 open or running | phase 2since Nov 17, 2014 | Nov 17, 2014 | none ahead |
| Aclaris Therapeutics | 10 open or running | phase 4since Dec 18, 2017 | Dec 18, 2017 | none ahead |
| Bayer | 10 open or running | phase 2since May 6, 2026 | May 6, 2026 | none ahead |
| eye-therapies-llc | 10 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since May 30, 2014 | May 30, 2014 | none ahead |
| Padagis | 10 open or running | phase 3since Nov 7, 2017 | Nov 7, 2017 | none ahead |
| Santen Pharmaceutical | 11 open or running | phase 3since Jul 3, 2024 | Jul 3, 2024 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | phase 1since Nov 23, 2021 | Nov 23, 2021 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Apr 10, 2019 | Apr 10, 2019 | none ahead |
Also a collaborator on its studies: quintiles-inc, ground-zero-pharmaceuticals, rho-inc and ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jan 10, 2011.
- Apr 13, 2012AbbVie's first study: phase 1 study in RosaceaNew to AbbVieAbbVie · NCT01579084 · 64 enrolled · United States
- Nov 26, 2012Phase 2 study in RosaceaAbbVie · NCT01735201 · 357 enrolled · United States
- Mar 21, 2014Phase 3 study in ErythemaAbbVie · NCT02095158 · 440 enrolled · United States
- May 5, 20142 phase 3 studies in ErythemaAbbVie · NCT02132117, NCT02131636
- May 30, 2014Johnson & Johnson's first study: phase 1 study in Rhinitis, AllergicNew to Johnson & JohnsonJohnson & Johnson · NCT02154334 · 47 enrolled · Germany
- Jul 21, 2014Phase 2 study in PresbyopiaAbbVie · NCT02197806 · 65 enrolled · United States
- Nov 17, 2014RDD Pharma's first study: phase 2 study in Fecal IncontinenceNew to RDD PharmaRDD Pharma · NCT02299557 · 19 enrolled · Hungary
- Nov 7, 2017Padagis's first study: phase 3 study in RosaceaNew to PadagisPadagis · NCT03352323 · 50 enrolled · United States
- Dec 18, 2017Aclaris Therapeutics's first study: phase 4 study in RosaceaNew to Aclaris TherapeuticsAclaris Therapeutics · NCT03380390 · 46 enrolled · United States
- May 7, 2018Phase 1 study in Fecal IncontinenceRDD Pharma · NCT03529487 · 40 enrolled · United States
- Apr 10, 2019Teva Pharmaceutical Industries's first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT03954444 · 1,105 enrolled · United States
- Nov 23, 2021Sun Pharmaceutical Industries's first study: phase 1 study in BioequivalenceNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT05148689 · 82 enrolled · United States
- Jul 3, 2024Santen Pharmaceutical's first study: phase 3 study in Acquired BlepharophimosisNew to Santen PharmaceuticalSanten Pharmaceutical · NCT06514612 · 234 planned · Czechia, France, Germany and more
- May 6, 2026Bayer's first study: phase 2 study in Nasal ObstructionNew to BayerBayer · NCT07582328 · 120 enrolled · Canada
TargetBeta
“Adrenergic receptor alpha agonist”ChEMBL 37, by rule
Other programs on the same 6 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07582328Nasal Obstruction · Canada | 2 | Completed | Bayer | May 28, 2026 | 120 |
| NCT06514612Acquired Blepharophimosis · Czechia, France, Germany and more | 3 | Recruiting | Santen Pharmaceutical | Aug 1, 2026 | 234 |
| NCT05148689Bioequivalence · United States | 1 | Completed | Sun Pharmaceutical Industries | Mar 21, 2019 | 82 |
| NCT03954444Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Jan 7, 2020 | 1,105 |
| NCT03529487Fecal Incontinence · United States | 1 | UNKNOWN | RDD Pharma | Dec 1, 2023 | 40 |
| NCT03380390Rosacea · United States | 4 | Completed | Aclaris Therapeutics | Jun 15, 2018 | 46 |
| NCT03352323Rosacea · United States | 3 | Completed | Padagis | Dec 6, 2017 | 50 |
| NCT02299557Fecal Incontinence · Hungary | 2 | Completed | RDD Pharma | Jun 2015 | 19 |
| NCT02197806Presbyopia · United States | 2 | Completed | AbbVie | Oct 2014 | 65 |
| NCT02154334Rhinitis, Allergic · Germany | 1 | Completed | Johnson & Johnson | Oct 2014 | 47 |
| NCT02132117Erythema · United States | 3 | Completed | AbbVie | Apr 2015 | 445 |
| NCT02131636Erythema · United States | 3 | Completed | AbbVie | Nov 2014 | 440 |
| NCT02095158Erythema · United States | 3 | Completed | AbbVie | Aug 2015 | 440 |
| NCT01735201Rosacea · United States | 2 | Completed | AbbVie | May 2013 | 357 |
| NCT01579084Rosacea · United States | 1 | Completed | AbbVie | Jun 2012 | 64 |
| NCT01275105Conjunctivitis, Allergic · United States | 2 | Completed | eye-therapies-llc | Mar 2011 | 68 |
How it is read
Names in the registry
- “Oxymetazoline”, 3 entries
- “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
- “Oxymetazoline Hydrochloride”, 2 entries
- “Oxymetazoline HCL Cream 1.0%”, 2 entries
- “AGN-199201”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 5 studies
- Erythema, 3 studies
- Fecal Incontinence, 2 studies
- Rhinitis, Allergic, 2 studies
- Nasal Obstruction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.